About: Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial
Creator	Kuijper, Ed Bootsma, Hester Cobbaert, Christa De Vries, Jutte Groeneveld, Geert Joosten, Simone Van Dissel, Jaap Van Der Reyden, Tanny
source	Medline; PMC
abstract	BACKGROUND: The inflammatory response in pneumococcal infection is primarily driven by immunoreactive bacterial cell wall components [lipoteichoic acid (LTA)]. An acute release of these components occurs when pneumococcal infection is treated with β-lactam antibiotics. OBJECTIVES: We hypothesized that non-lytic rifampicin compared with lytic β-lactam antibiotic treatment would attenuate the inflammatory response in patients with pneumococcal pneumonia. METHODS: In the PRISTINE (Pneumonia treated with RIfampicin aTtenuates INflammation) trial, a randomized, therapeutic controlled, exploratory study in patients with community-acquired pneumococcal pneumonia, we looked at LTA release and inflammatory and clinical response during treatment with both rifampicin and β-lactam compared with treatment with β-lactam antibiotics only. The trial is registered in the Dutch trial registry, number NTR3751 (European Clinical Trials Database number 2012-003067-22). RESULTS: Forty-one patients with community-acquired pneumonia were included; 17 of them had pneumococcal pneumonia. LTA release, LTA-mediated inflammatory responses, clinical outcomes, inflammatory biomarkers and transcription profiles were not different between treatment groups. CONCLUSIONS: The PRISTINE study demonstrated the feasibility of adding rifampicin to β-lactam antibiotics in the treatment of community-acquired pneumococcal pneumonia, but, despite solid in vitro and experimental animal research evidence, failed to demonstrate a difference in plasma LTA concentrations and subsequent inflammatory and clinical responses. Most likely, an inhibitory effect of human plasma contributes to the low immune response in these patients. In addition, LTA plasma concentration could be too low to mount a response via Toll-like receptor 2 in vitro, but may nonetheless have an effect in vivo.
has issue date	2019-05-18(xsd:dateTime)
bibo:doi	10.1093/jac/dkz207
bibo:pmid	31106377
has license	cc-by-nc
sha1sum (hex)	c98075a839f10763a8c30207b33c57e4455bc4ae
schema:url	https://doi.org/10.1093/jac/dkz207
resource representing a document's title	Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial
has PubMed Central identifier	PMC6640306
has PubMed identifier	31106377
schema:publication	J Antimicrob Chemother
resource representing a document's body	covid:c98075a839f10763a8c30207b33c57e4455bc4ae#body_text
is schema:about of	named entity 'NON-' named entity 'TREATED WITH' named entity 'BACKGROUND' named entity 'LACTAM ANTIBIOTICS' named entity 'inflammatory response' named entity 'RELEASE' named entity 'TRIAL' named entity 'ACUTE' named entity 'DRIVEN' named entity 'ATTENUATE' named entity 'ANTIBIOTIC TREATMENT' named entity 'LYTIC' named entity 'DOES NOT' named entity 'ACQUIRED' named entity 'COMMUNITY' named entity 'PNEUMOCOCCAL PNEUMONIA' named entity 'INFLAMMATION' named entity 'ACID' named entity 'PNEUMOCOCCAL INFECTION' named entity 'BACTERIAL CELL WALL' named entity 'INFLAMMATORY RESPONSE' named entity 'THESE' named entity 'COMPONENTS' covid:arg/c98075a839f10763a8c30207b33c57e4455bc4ae named entity 'lipoteichoic acid' named entity 'attenuate' named entity 'pneumococcal infection' named entity 'LTA' named entity 'lipoteichoic acid' named entity 'pneumococcal infection' named entity 'pneumococcal pneumonia' named entity 'Corticosteroid therapy' named entity 'LTA' named entity 'control group' named entity 'rifamycins' named entity 'morbidity' named entity 'treatment for pneumococcal pneumonia' named entity 'C-reactive protein' named entity 'serotype' named entity 'combination therapy' named entity 'Declaration of Helsinki' named entity 'quinolone' named entity 'pneumococcal' named entity 'bacterial cell wall' named entity 'LTA' named entity 'serotype' named entity 'meningitis' named entity 'LTA' named entity 'Gram-positive' named entity 'long-term' named entity 'pneumococcal meningitis' named entity 'LTA' named entity 'inflammatory response' named entity 'nasopharyngeal swab' named entity 'Netherlands' named entity 'pneumococcal pneumonia' named entity 'pneumococcal infection' named entity 'PLS' named entity 'biomarkers' named entity 'LTA' named entity 'pneumonia' named entity 'LTA' named entity 'serotypes' named entity 'pneumococcal pneumonia' named entity 'adjunctive treatment' named entity 'lytic' named entity 'biomarkers' named entity 'blood culture' named entity 'assay' named entity 'blood culture' named entity 'b-lactam' named entity 'pneumonia' named entity 'medical history' named entity 'antigen test'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software